RT Journal Article
SR Electronic
T1 Post-SARS-CoV-2 Onset Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Symptoms in Two Cohort Studies of COVID-19 Recovery
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.08.24316976
DO 10.1101/2024.11.08.24316976
A1 Jamal, Armaan
A1 Dalhuisen, Thomas
A1 Gallego Márquez, Nuria
A1 Dziarski, Alisha D.
A1 Uy, Julian
A1 Walch, Samantha N.
A1 Thomas, Sean A.
A1 Fehrman, Emily A.
A1 Romero, Arianna E.
A1 Zelaya, Ashley S.
A1 Akasreku, Enam A.
A1 Adeagbo, Tamilore V.
A1 Pasetes, Elizabeth C.
A1 Akbas, Selin Y.
A1 Azola, Alba M.
A1 Deeks, Steven G.
A1 Kelly, J. Daniel
A1 Martin, Jeffrey N.
A1 Henrich, Timothy J.
A1 Landay, Alan L.
A1 Peluso, Michael J.
A1 Antar, Annukka A. R.
YR 2024
UL http://medrxiv.org/content/early/2024/11/08/2024.11.08.24316976.abstract
AB Objective To determine how many people with long COVID also meet diagnostic criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Methods We identified which participants with long COVID also met the Institute of Medicine (IOM) or the 2003 Canadian Consensus Criteria (CCC) for ME/CFS at approximately 6-8 months post-SARS-CoV-2 infection in two cohorts: (1) the JHU COVID Recovery cohort, which enrolled participants within 4 weeks of infection and (2) the Long-term Impact of Infection with Novel Coronavirus (LIINC) cohort, which enriched for participants with long COVID. Neither study administered ME/CFS-specific surveys, so available data elements were mapped onto each ME/CFS diagnostic criteria.Results Of 97 JHU participants with long COVID, 5 met IOM criteria and 2 met CCC criteria. Of 281 LIINC participants with long COVID, 51 met the IOM criteria and 29 met the CCC criteria. In LIINC, participants with long COVID meeting ME/CFS criteria were more likely to be female and report a greater number of post-COVID symptoms (p<0.001).Conclusions The co-occurrence of ME/CFS symptoms and long COVID suggests that SARS-CoV-2 is a cause of ME/CFS. ME/CFS-specific measures should be incorporated into studies of post-acute COVID-19 to advance studies of post-SARS-CoV-2 onset ME/CFS.Competing Interest StatementDr. Henrich reports grants from Merck & Co, Gilead Sciences, and Bristol-Myers Squibb, and has provided consulting for Roche, outside the submitted work. Dr. Deeks reports grants and/or personal fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences, outside the submitted work. MJP has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi, outside the submitted work. All other authors report there are no competing interests to declare.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/37104709/ Funding StatementThis work was supported by The Foundation for AIDS Research under grant 110180-69-RSCV; the NIH/NIAID under grants 3R01AI141003-03S1, R01AI158013, K08AI143391, K23AI157875 and U19AI159822-S; NINDS under grant R01NS136197; the PolyBio Research Foundation; and the Johns Hopkins University Center for AIDS Research (JHU CFAR), an NIH funded program under Grant P30AI094189. The JHU CFAR is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Johns Hopkins University School of Medicine Institutional Review Board gave ethical approval for this work. The UCSF Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data sets analyzed for this study are available from the corresponding authors on reasonable request pending IRB approval.